In lung adenocarcinomas, CRKL amplification may be associated with resistance to EGFR-directed therapy (Cheung et al, 2011). However, its significance in urothelial cancer is yet to be determined.

CRKL (Crk-like protein) is a substrate of the BCR-ABL tyrosine kinase, and plays a role in fibroblast transformation by BCR-ABL. It is potentially oncogenic. In lung adenocarcinomas, CRKL amplification may be associated with resistance to anti-EGFR therapy.